BioHarvest Sciences Inc. (NASDAQ: BHST) announced plans to dual-list its shares on the Tel Aviv Stock Exchange (TASE) by September 8, 2026, as part of a strategy to broaden investor access and strengthen its presence in Israel.
The Vancouver-based, Israel-founded company, which develops plant-based compounds through its botanical synthesis technology platform, will list 22,667,842 common shares on the TASE. The dual listing will operate alongside its existing NASDAQ listing, where shares trade under the ticker BHST, with a Hebrew symbol of בהסט.
The company, which functions as a contract development and manufacturing organization (CDMO) for plant-based compounds while also developing proprietary nutraceutical products, will continue to file all U.S. Securities and Exchange Commission disclosures through the EDGAR system, with simultaneous submissions to the MAGNA Disclosure System for TASE compliance.
BioHarvest Sciences has also disclosed details of its outstanding share structure, including up to 4,516,021 common shares reserved for future issuance under its equity incentive plan, 610,742 shares issuable upon exercise of investor warrants, and 2,564,876 outstanding options to purchase common shares. Additional restricted share units total 269,521, with 1,681,624 shares remaining available for future grants.
Dr. Zaki Rakib, CEO of BioHarvest Sciences, described the dual listing as a natural step for the company, emphasizing its aim to deepen engagement with Israeli investors and enhance liquidity for its shares.
